reference stringlengths 68 167 | prediction stringlengths 67 166 | wer float64 0.05 0.38 | cer float64 0.01 0.11 | entities stringlengths 91 124 | entity_cer float64 0.03 0.57 | audio audioduration (s) 5.01 16.1 |
|---|---|---|---|---|---|---|
Please evaluate Mr. Jones for eligibility for depemokimab, as he has severe eosinophilic asthma despite current therapy. | Please evaluate Mr. Jones for eligibility for DiPemicimab, as he has severe eosinophilic asthma despite current therapy. | 0.058824 | 0.025641 | "[{\"text\": \"depemokimab\", \"category\": \"drug\", \"char_start\": 46, \"char_end\": 57}]" | 0.454545 | |
Abdominal ultrasound performed to assess liver parenchyma given patient's history of familial chylomicronemia syndrome and initiation of plozasiran. | Abdominal ultrasound performed to assess liver parenchyma given patients history of familial chylamycronemia syndrome and initiation of plazocerin. | 0.166667 | 0.054422 | "[{\"text\": \"plozasiran\", \"category\": \"drug\", \"char_start\": 137, \"char_end\": 147}]" | 0.5 | |
Patients receiving donidalorsen demonstrated a significant reduction in the frequency of hereditary angioedema attacks during the study period. | Patients receiving Donadellerson demonstrated a significant reduction in the frequency of hereditary angiotima attacks during the study period. | 0.111111 | 0.056338 | "[{\"text\": \"donidalorsen\", \"category\": \"drug\", \"char_start\": 19, \"char_end\": 31}]" | 0.416667 | |
Patient discharged with a prescription for tradipitant for motion sickness prevention. | Patient discharged with a prescription for tritipidant for motion sickness prevention. | 0.090909 | 0.035294 | "[{\"text\": \"tradipitant\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 54}]" | 0.272727 | |
Initiate gepotidacin 1500 mg BID for three days for her acute uncomplicated cystitis. | initiate Jeppetituson 1500 mg bid for three days for her acute uncomplicated cystitis. | 0.076923 | 0.083333 | "[{\"text\": \"gepotidacin\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 20}]" | 0.545455 | |
Prescribe fitusiran, 80 mg subcutaneously once monthly, for bleeding prophylaxis in this patient with hemophilia B and inhibitors. | Prescribe Fiducerin, 80 mg subcutaneously once monthly, for bleeding prophylaxis in this patient with hemophilia B and inhibitors. | 0.055556 | 0.031496 | "[{\"text\": \"fitusiran\", \"category\": \"drug\", \"char_start\": 10, \"char_end\": 19}]" | 0.555556 | |
Given his persistent symptoms from obstructive hypertrophic cardiomyopathy, we are referring him for a cardiology opinion regarding aficamten. | Given his persistent symptoms from obstructive hypertrophic cardiomyopathy, we are referring him for a cardiology opinion regarding a ficumton. | 0.111111 | 0.021429 | "[{\"text\": \"aficamten\", \"category\": \"drug\", \"char_start\": 132, \"char_end\": 141}]" | 0.222222 | |
Clinical history includes familial chylomicronemia syndrome, currently managed with olezarsen, presenting with epigastric discomfort. | Clinical history includes familial chylamycronemia syndrome, currently managed with Olsarsen, presenting with epigastric discomfort. | 0.142857 | 0.030769 | "[{\"text\": \"olezarsen\", \"category\": \"drug\", \"char_start\": 84, \"char_end\": 93}]" | 0.333333 | |
Initiate levacetylleucine for the neurological manifestations of Niemann-Pick type C disease. | Initiate Levusetilucine for the neurological manifestations of Neem and Pick Type C disease. | 0.25 | 0.086957 | "[{\"text\": \"levacetylleucine\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 25}]" | 0.375 | |
Plan to initiate therapy with obecabtagene autoleucel for the patient's relapsed B-cell acute lymphoblastic leukemia. | Plan to initiate therapy with OPEC-Optaging Otolusal for the patient's relapsed B-cell, acute lymphoblastic leukemia. | 0.1875 | 0.094828 | "[{\"text\": \"obecabtagene autoleucel\", \"category\": \"drug\", \"char_start\": 30, \"char_end\": 53}]" | 0.565217 | |
The patient was randomized to receive inavolisib in combination with palbociclib and fulvestrant as per the study arm. | The patient was randomized to receive enavalizib in combination with palbicyclobe and full vestrant, as per the study arm. | 0.222222 | 0.076923 | "[{\"text\": \"inavolisib\", \"category\": \"drug\", \"char_start\": 38, \"char_end\": 48}]" | 0.3 | |
We plan to initiate sibeprenlimab for her IgA nephropathy to help reduce her significant proteinuria. | We plan to initiate Cyprinlemab for her IgA nephropathy to help reduce her significant protonuria. | 0.133333 | 0.08 | "[{\"text\": \"sibeprenlimab\", \"category\": \"drug\", \"char_start\": 20, \"char_end\": 33}]" | 0.461538 | |
Topical beremagene geperpavec was discussed with the family as a potential treatment option for the patient's dystrophic epidermolysis bullosa wounds. | Topical barimaging jeppapevic was discussed with the family as a potential treatment option for the patient's dystrophic epidermalysis bullosa wounds. | 0.15 | 0.067114 | "[{\"text\": \"beremagene geperpavec\", \"category\": \"drug\", \"char_start\": 8, \"char_end\": 29}]" | 0.428571 | |
Overall, the extent of metastatic disease remains stable on current zongertinib therapy. | Overall, the extent of metastatic disease remains stable on current Zangatinib therapy. | 0.083333 | 0.034884 | "[{\"text\": \"zongertinib\", \"category\": \"drug\", \"char_start\": 68, \"char_end\": 79}]" | 0.363636 | |
Following surgical resection, we are initiating vorasidenib as adjuvant therapy for his IDH-mutant grade 2 astrocytoma. | Following surgical resection, we are initiating Voricidinib as adjuvant therapy for his IDH mutant grade 2 astrocytoma. | 0.058824 | 0.025641 | "[{\"text\": \"vorasidenib\", \"category\": \"drug\", \"char_start\": 48, \"char_end\": 59}]" | 0.363636 | |
Prescribe paltusotine 30 mg orally once daily for ongoing management of her acromegaly. | Prescribe Paltus Artin 30 mg orally once daily for ongoing management of her acromegaly. | 0.153846 | 0.046512 | "[{\"text\": \"paltusotine\", \"category\": \"drug\", \"char_start\": 10, \"char_end\": 21}]" | 0.272727 | |
Brain MRI demonstrates no acute intracranial pathology to account for the patient's menopausal vasomotor symptoms, currently managed with elinzanetant. | Brain MRI demonstrates no acute intracranial pathology to account for the patient's menopausal vasomotor symptoms, currently managed with a linsenetant. | 0.105263 | 0.026846 | "[{\"text\": \"elinzanetant\", \"category\": \"drug\", \"char_start\": 138, \"char_end\": 150}]" | 0.25 | |
Given the recent FDA approval, we plan to initiate the patient on doxecitine and doxribtimine for their thymidine kinase 2 deficiency. | Given the recent FDA approval, we plan to initiate the patient on Duxocetine and Duxryptamine for their thymidine kinase II deficiency. | 0.142857 | 0.068182 | "[{\"text\": \"doxecitine and doxribtimine\", \"category\": \"drug\", \"char_start\": 66, \"char_end\": 93}]" | 0.333333 | |
The patient received a single oral dose of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea. | The patient received a single oral dose of xalifladasin for the treatment of uncomplicated urogenital gonorrhea. | 0.0625 | 0.036036 | "[{\"text\": \"zoliflodacin\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 55}]" | 0.333333 | |
Considering his persistently elevated LDL despite maximal statin therapy, we are evaluating the potential for initiating lerodalcibep as a monthly subcutaneous option. | Considering his persistently elevated LDL despite maximal statin therapy, we are evaluating the potential for initiating Lerodalcybe as a monthly subcutaneous option. | 0.045455 | 0.012121 | "[{\"text\": \"lerodalcibep\", \"category\": \"drug\", \"char_start\": 121, \"char_end\": 133}]" | 0.25 | |
Datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival compared to standard of care in the study population. | Data Potomab Derek Stechen demonstrated a statistically significant improvement in progression-free survival compared to standard of care in the study population. | 0.2 | 0.057325 | "[{\"text\": \"Datopotamab deruxtecan\", \"category\": \"drug\", \"char_start\": 0, \"char_end\": 22}]" | 0.318182 | |
Patient discharged on nerandomilast 25 mg twice daily for continued management of her idiopathic pulmonary fibrosis. | patient discharged on narendromolast 25 mg twice daily for continued management of her idiopathic pulmonary fibrosis. | 0.0625 | 0.034783 | "[{\"text\": \"nerandomilast\", \"category\": \"drug\", \"char_start\": 22, \"char_end\": 35}]" | 0.230769 | |
The patient was discharged on resmetirom for their noncirrhotic MASH with moderate liver fibrosis, per recent EMA approval. | The patient was discharged on resmediram for their non-serotic mash with moderate liver fibrosis, per recent EMA approval. | 0.166667 | 0.049587 | "[{\"text\": \"resmetirom\", \"category\": \"drug\", \"char_start\": 30, \"char_end\": 40}]" | 0.2 | |
Start penpulimab 200 mg IV every three weeks for recurrent nasopharyngeal carcinoma. | Start Pimpulum at 200 mg, IV, every three weeks for recurrent nasal pharyngeal carcinoma. | 0.333333 | 0.096386 | "[{\"text\": \"penpulimab\", \"category\": \"drug\", \"char_start\": 6, \"char_end\": 16}]" | 0.5 | |
Initiate ziftomenib 200 mg orally once daily for relapsed NPM1-mutated AML, monitoring for differentiation syndrome. | Initiate Ziftonib 200 mg orally once daily, for relapsed NPM1 mutated AML. Monitoring for differentiation syndrome. | 0.0625 | 0.017544 | "[{\"text\": \"ziftomenib\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 19}]" | 0.3 | |
No acute changes demonstrated on orbital CT; patient continues acoltremon for chronic dry eye disease. | No acute changes demonstrated on orbital CT. Patient continues accultremon for chronic dry eye disease. | 0.066667 | 0.02 | "[{\"text\": \"acoltremon\", \"category\": \"drug\", \"char_start\": 63, \"char_end\": 73}]" | 0.1 | |
Clinical history notes IgA nephropathy with significant proteinuria, for which the patient recently initiated atrasentan. | Clinical history notes IgA nephropathy with significant protonuria, for which the patient recently initiated atracentin. | 0.133333 | 0.033613 | "[{\"text\": \"atrasentan\", \"category\": \"drug\", \"char_start\": 110, \"char_end\": 120}]" | 0.2 | |
Follow-up MRI of the lower extremities performed to assess disease progression in a Duchenne patient receiving givinostat. | Follow-up MRI of the lower extremities performed to assess disease progression in a dachen patient receiving givinastat. | 0.111111 | 0.033058 | "[{\"text\": \"givinostat\", \"category\": \"drug\", \"char_start\": 111, \"char_end\": 121}]" | 0.1 | |
We are referring Mr. Smith for consideration of telisotuzumab vedotin given his locally advanced non-squamous NSCLC with high c-Met overexpression. | We are referring Mr. Smith for consideration of Telesatus Yumapvedatin, given his locally advanced nonsquamous NSCLC, with high C-MET over expression. | 0.272727 | 0.068966 | "[{\"text\": \"telisotuzumab vedotin\", \"category\": \"drug\", \"char_start\": 48, \"char_end\": 69}]" | 0.333333 | |
We are considering garadacimab for prophylaxis to prevent further hereditary angioedema attacks in this patient. | We are considering Geridasmab for prophylaxis to prevent further hereditary angiotema attacks in this patient. | 0.133333 | 0.054054 | "[{\"text\": \"garadacimab\", \"category\": \"drug\", \"char_start\": 19, \"char_end\": 30}]" | 0.454545 | |
We are considering initiating narsoplimab for her refractory transplant-associated thrombotic microangiopathy. | We are considering initiating Narsoplimam for her refractory, transplant-associated thrombotic microangiopathy. | 0.083333 | 0.009174 | "[{\"text\": \"narsoplimab\", \"category\": \"drug\", \"char_start\": 30, \"char_end\": 41}]" | 0.181818 | |
Patient discharged with a prescription for suzetrigine 50 mg twice daily for ongoing acute pain management. | Patient discharged with a prescription for Suzatrogen 50 mg twice daily, for ongoing acute pain management. | 0.0625 | 0.037736 | "[{\"text\": \"suzetrigine\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 54}]" | 0.454545 | |
Prescribe sebetralstat 80 mg by mouth as needed for acute hereditary angioedema attacks. | Prescribe Sabatralstet 80 mg by mouth as needed for acute hereditary angiotema attacks. | 0.153846 | 0.057471 | "[{\"text\": \"sebetralstat\", \"category\": \"drug\", \"char_start\": 10, \"char_end\": 22}]" | 0.333333 | |
Patient was started on delgocitinib cream for her moderate-to-severe chronic hand eczema due to inadequate response to previous topical treatments. | Patient was started on Delgacitinib cream for her moderate to severe chronic hand eczema, due to inadequate response to previous topical treatments. | 0.045455 | 0.006849 | "[{\"text\": \"delgocitinib\", \"category\": \"drug\", \"char_start\": 23, \"char_end\": 35}]" | 0.166667 | |
Patients receiving dordaviprone demonstrated a statistically significant improvement in overall survival compared to placebo. | Patients receiving daudaviproin demonstrated a statistically significant improvement in overall survival compared to placebo. | 0.071429 | 0.032258 | "[{\"text\": \"dordaviprone\", \"category\": \"drug\", \"char_start\": 19, \"char_end\": 31}]" | 0.25 | |
Stable disease noted in the setting of ongoing avutometinib therapy. | Stable disease noted in the setting of ongoing avutomtenib therapy. | 0.1 | 0.029851 | "[{\"text\": \"avutometinib\", \"category\": \"drug\", \"char_start\": 47, \"char_end\": 59}]" | 0.166667 | |
Patients in cohort A received a single infusion of etuvetidigene autotemcel following myeloablative conditioning. | Patients in cohort A received a single infusion of eduvetidigine autotemcel following myeloblative conditioning. | 0.142857 | 0.026786 | "[{\"text\": \"etuvetidigene autotemcel\", \"category\": \"drug\", \"char_start\": 51, \"char_end\": 75}]" | 0.083333 | |
No acute intracranial hemorrhage or significant lymphadenopathy is identified in this patient with Wiskott-Aldrich syndrome. | No acute intracranial hemorrhage or significant lymphadenopathy is identified in this patient with Wiskaw-Taldrich syndrome. | 0.125 | 0.03252 | "[{\"text\": \"Wiskott-Aldrich syndrome\", \"category\": \"condition\", \"char_start\": 99, \"char_end\": 123}]" | 0.208333 | |
We are referring this patient for allogeneic hematopoietic stem cell transplantation, and recommend a preparative conditioning regimen including treosulfan. | We are referring this patient for allogeneic hematopoietic stem cell transplantation and recommend a preparative conditioning regimen, including triosulfin. | 0.052632 | 0.012987 | "[{\"text\": \"treosulfan\", \"category\": \"drug\", \"char_start\": 145, \"char_end\": 155}]" | 0.2 | |
We are evaluating aceclidine as a potential non-surgical treatment for her symptomatic presbyopia to enhance near vision. | We are evaluating a seclidine as a potential nonsurgical treatment for her symptomatic presbyopia to enhance near vision. | 0.222222 | 0.025 | "[{\"text\": \"aceclidine\", \"category\": \"drug\", \"char_start\": 18, \"char_end\": 28}]" | 0.1 | |
Plan for Meduloc intramedullary fixation of the right fifth metacarpal shaft fracture. | Plan for medulock intramedullary fixation of the right fifth metacouple shaft fracture. | 0.166667 | 0.058824 | "[{\"text\": \"Meduloc intramedullary fixation\", \"category\": \"procedure\", \"char_start\": 9, \"char_end\": 40}]" | 0.032258 | |
Given the diagnosis of H3 K27M-mutant diffuse midline glioma, please prescribe dordaviprone as per protocol. | Given the diagnosis of H3K27M mutant, diffuse midline glioma, please prescribe Daudevipron as per protocol. | 0.1875 | 0.04717 | "[{\"text\": \"H3 K27M-mutant diffuse midline glioma\", \"category\": \"condition\", \"char_start\": 23, \"char_end\": 60}]" | 0.054054 | |
No new intracranial abnormalities are identified following the initiation of sepiapterin. | No new intracranial abnormalities are identified following the initiation of sepiaptorine. | 0.090909 | 0.022727 | "[{\"text\": \"sepiapterin\", \"category\": \"drug\", \"char_start\": 77, \"char_end\": 88}]" | 0.090909 | |
Initiate pembrolizumab and berahyaluronidase alfa subcutaneously for her metastatic lung adenocarcinoma. | Initiate Pembrolyzumab and Barahialeronidase alpha subcutaneously for her metastatic lung adenocarcinoma. | 0.272727 | 0.058252 | "[{\"text\": \"pembrolizumab and berahyaluronidase alfa\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 49}]" | 0.175 | |
Eligible subjects with inoperable plexiform neurofibromas due to neurofibromatosis type 1 were randomized to mirdametinib or placebo. | Eligible subjects with inoperable plexiform neurofibromas due to neurofibromatosis type 1 were randomized to myrrh dimetinib or placebo. | 0.117647 | 0.037879 | "[{\"text\": \"mirdametinib\", \"category\": \"drug\", \"char_start\": 109, \"char_end\": 121}]" | 0.166667 | |
Eligibility for dordaviprone required confirmation of the H3 K27M histone mutation in patients with diffuse midline glioma. | Eligibility for dordoviprone required confirmation of the H3K27M histone mutation in patients with diffuse midline glioma. | 0.176471 | 0.016393 | "[{\"text\": \"H3 K27M histone mutation\", \"category\": \"biomarker\", \"char_start\": 58, \"char_end\": 82}]" | 0.041667 | |
Patient will be discharged on oral elamipretide 40 mg twice daily for his Barth syndrome, with close follow-up. | Patient will be discharged on oral, Elamopredide 40 mg twice daily for his Barth syndrome, with close follow-up. | 0.052632 | 0.018349 | "[{\"text\": \"elamipretide\", \"category\": \"drug\", \"char_start\": 35, \"char_end\": 47}]" | 0.25 | |
Start sevabertinib 150 mg PO BID for HER2-mutated NSCLC with CNS metastases. | Start Cevibrtenib 150 mg pole bit for HER2 mutated NS-CLC with CNS metastases. | 0.384615 | 0.106667 | "[{\"text\": \"sevabertinib\", \"category\": \"drug\", \"char_start\": 6, \"char_end\": 18}]" | 0.333333 | |
Follow-up CT scan demonstrates stable osseous disease, indicating a persistent response to linvoseltamab treatment. | Follow-up CT scan demonstrates stable Ossias disease, indicating a persistent response to linovaciltamab treatment. | 0.133333 | 0.061947 | "[{\"text\": \"linvoseltamab\", \"category\": \"drug\", \"char_start\": 91, \"char_end\": 104}]" | 0.230769 | |
The patient is discharged home to continue sunvozertinib 300 mg daily for their EGFR exon 20 insertion mutated NSCLC. | The patient is discharged home to continue Sunvoser Tinnip 300 mg daily for their EGFR-Xon 20 insertion mutated NS-CLC. | 0.263158 | 0.051724 | "[{\"text\": \"sunvozertinib\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 56}]" | 0.307692 |
Evaluation Results: whisper-small
Evaluation results from Whisper model evaluation.
Summary
| Model | WER | CER |
|---|---|---|
| openai/whisper-small | 12.95% | 4.24% |
Source Data
- Evaluation Dataset: Trelis/medical-terms-2025
- Model Evaluated: openai/whisper-small
Columns
| Column | Description |
|---|---|
audio |
Audio sample (if available from source dataset) |
reference |
Ground truth transcription |
prediction |
Model prediction |
wer |
Word Error Rate for this sample |
cer |
Character Error Rate for this sample |
| entities | Entity annotations from source dataset |
| entity_cer | Per-sample entity CER (-1.0 if no entities) |
Entity CER
Overall Entity CER: 26.40%
| Category | CER |
|---|---|
| biomarker | 4.17% |
| condition | 11.48% |
| drug | 29.92% |
| procedure | 3.23% |
Generated by Trelis Studio
- Downloads last month
- 20